WO1982001867A1 - Pharmaceutical compound and method - Google Patents
Pharmaceutical compound and method Download PDFInfo
- Publication number
- WO1982001867A1 WO1982001867A1 PCT/AU1981/000164 AU8100164W WO8201867A1 WO 1982001867 A1 WO1982001867 A1 WO 1982001867A1 AU 8100164 W AU8100164 W AU 8100164W WO 8201867 A1 WO8201867 A1 WO 8201867A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- glycerol
- zinc
- pharmaceutical compound
- temperature
- compound according
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 39
- 238000000034 method Methods 0.000 title claims description 16
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 103
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims abstract description 56
- LRGQZEKJTHEMOJ-UHFFFAOYSA-N propane-1,2,3-triol;zinc Chemical compound [Zn].OCC(O)CO LRGQZEKJTHEMOJ-UHFFFAOYSA-N 0.000 claims abstract description 35
- 239000013078 crystal Substances 0.000 claims abstract description 28
- 239000011787 zinc oxide Substances 0.000 claims abstract description 28
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 10
- 241000276425 Xiphophorus maculatus Species 0.000 claims abstract description 9
- 239000007795 chemical reaction product Substances 0.000 claims abstract description 6
- 239000002537 cosmetic Substances 0.000 claims abstract description 6
- 230000000069 prophylactic effect Effects 0.000 claims abstract description 5
- 239000000203 mixture Substances 0.000 claims description 23
- 238000006243 chemical reaction Methods 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- KKEBXNMGHUCPEZ-UHFFFAOYSA-N 4-phenyl-1-(2-sulfanylethyl)imidazolidin-2-one Chemical compound N1C(=O)N(CCS)CC1C1=CC=CC=C1 KKEBXNMGHUCPEZ-UHFFFAOYSA-N 0.000 claims description 12
- 239000002245 particle Substances 0.000 claims description 12
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 claims description 10
- 239000004246 zinc acetate Substances 0.000 claims description 10
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 9
- 229910052751 metal Inorganic materials 0.000 claims description 9
- 239000002184 metal Substances 0.000 claims description 9
- 230000008569 process Effects 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 9
- 239000011541 reaction mixture Substances 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 7
- 239000002002 slurry Substances 0.000 claims description 5
- 239000011701 zinc Substances 0.000 claims description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 4
- 239000004166 Lanolin Substances 0.000 claims description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 4
- 229940039717 lanolin Drugs 0.000 claims description 4
- 235000019388 lanolin Nutrition 0.000 claims description 4
- 229910052725 zinc Inorganic materials 0.000 claims description 4
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 3
- 229910052802 copper Inorganic materials 0.000 claims description 3
- 239000010949 copper Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 230000000475 sunscreen effect Effects 0.000 claims description 3
- 239000000516 sunscreening agent Substances 0.000 claims description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 2
- 239000005642 Oleic acid Substances 0.000 claims description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 2
- 239000005662 Paraffin oil Substances 0.000 claims description 2
- 235000019483 Peanut oil Nutrition 0.000 claims description 2
- 235000021355 Stearic acid Nutrition 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 claims description 2
- 150000001879 copper Chemical class 0.000 claims description 2
- PMKLVGOZGNPKLG-UHFFFAOYSA-H dialuminum;2',4',5',7'-tetraiodo-3-oxospiro[2-benzofuran-1,9'-xanthene]-3',6'-diolate Chemical compound [Al+3].[Al+3].O1C(=O)C2=CC=CC=C2C21C1=CC(I)=C([O-])C(I)=C1OC1=C(I)C([O-])=C(I)C=C21.O1C(=O)C2=CC=CC=C2C21C1=CC(I)=C([O-])C(I)=C1OC1=C(I)C([O-])=C(I)C=C21.O1C(=O)C2=CC=CC=C2C21C1=CC(I)=C([O-])C(I)=C1OC1=C(I)C([O-])=C(I)C=C21 PMKLVGOZGNPKLG-UHFFFAOYSA-H 0.000 claims description 2
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 claims description 2
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 claims description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 2
- 239000000312 peanut oil Substances 0.000 claims description 2
- 239000008257 shaving cream Substances 0.000 claims description 2
- 239000008117 stearic acid Substances 0.000 claims description 2
- UJMBCXLDXJUMFB-GLCFPVLVSA-K tartrazine Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)C1=NN(C=2C=CC(=CC=2)S([O-])(=O)=O)C(=O)C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 UJMBCXLDXJUMFB-GLCFPVLVSA-K 0.000 claims description 2
- 235000012756 tartrazine Nutrition 0.000 claims description 2
- 239000004149 tartrazine Substances 0.000 claims description 2
- 229960000943 tartrazine Drugs 0.000 claims description 2
- 235000011187 glycerol Nutrition 0.000 claims 14
- 238000001816 cooling Methods 0.000 claims 5
- 238000001035 drying Methods 0.000 claims 5
- 238000001914 filtration Methods 0.000 claims 5
- 238000005406 washing Methods 0.000 claims 5
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 238000004040 coloring Methods 0.000 claims 1
- 235000021313 oleic acid Nutrition 0.000 claims 1
- 239000000969 carrier Substances 0.000 abstract 1
- 238000003756 stirring Methods 0.000 description 12
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 239000000047 product Substances 0.000 description 7
- 238000011282 treatment Methods 0.000 description 6
- 208000017520 skin disease Diseases 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 239000011573 trace mineral Substances 0.000 description 3
- 235000013619 trace mineral Nutrition 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 150000003751 zinc Chemical class 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012444 Dermatitis diaper Diseases 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960003280 cupric chloride Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 206010021198 ichthyosis Diseases 0.000 description 1
- 229910000000 metal hydroxide Inorganic materials 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 150000003752 zinc compounds Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/27—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/20—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing organic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C29/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
- C07C29/68—Preparation of metal alcoholates
- C07C29/70—Preparation of metal alcoholates by converting hydroxy groups to O-metal groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C31/00—Saturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
- C07C31/28—Metal alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/10—General cosmetic use
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/58—Metal complex; Coordination compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q9/00—Preparations for removing hair or for aiding hair removal
- A61Q9/02—Shaving preparations
Definitions
- This invention relates to certain pharmaceutical compounds and to their use for therapeutic and prophylactic treatment of the human body and for veterinary purposes.
- the invention relates to use of metal glycerolate compounds as a base for
- metal zinc is necessary in trace element form for cell division and tissue repair and also in-various compounds has a knovn slight bactericidal and fungicidal action on the
- Crystalline glycerato-metal complexes were first described in a paper in the Australian Journal of Chemistry volume 23, 1970, Page 1,963 and in that paper the method of forming these compounds and some of their physical properties are given. These compounds form during the heating of particular metal oxides, hydroxides or salts with glycerol at temperatures around 120° or higher.
- the physical structure of the resulting chelated compounds generally produces a platy morphology resulting in a talc-like or slippery tactile impression.
- glycerato-metal complexes can be arranged to give valuable advantage in the treatment of various medical disorders, and extends to a method of treatment of skin disorders comprising the step of applying to the affected skin a modified zinc glycerolate complex including a pharmaceutically acceptable carrier or extender, or the compound may be" used as a barrier substance or a sun screen or as a protective surface of high lubricity when applied to the skin.
- OMPI IPO subsequently chemically altered by certain reagents to achieve a composition which may recommend its use because of specific effects in particular topical skin application whether for therapeutic or cosmetic purposes while maintaining the advantageous physical properties.
- any zinc salt or compound which decomposes to ZnO on heating at temperatures between approximately 120-300°C will form this compound.
- the heating of zinc acetate and glycerol forms a zinc glycerolate complex via a solution phase.
- OMPI variation in size of the relatively thin platlets so that smaller crystals fit into the spaces between larger crystals and provide a highly successful protective screen.
- FIG. 1 herein shows a drawing taken from a photograph of crystals of zinc glycerolate, using a magnification of 9000, and
- FIG. 2 shows one of the crystals, illustrating their plate-like nature, the photograph of that crystal having a magnification of 18,000.
- FIG. 1 shows a large crystal 1 with medium sized crystals 2 and a range of sizes down to the smaller crystals 3, all however retaining thei ⁇ characteristic of elongated hexagonal configuration with relatively low thickness .
- crystals can beproduced from either zinc oxide or zinc acetate when reacted with glycerol, but preferably zinc oxide is the medium used in that it produces the platlets illustrated, whereas the product formed by precipitation from the solution phase of zinc acetate in heated glycerol may exhibit additional particles the shape and size of which may detract from the overall lubricity.
- the zinc glycerolate appears to conform to the general formulae C HgO ⁇ Zn and the complex is most suitably formed from the high temperature heating with vigorous stirring of zinc oxide in glycerol.
- zinc acetate can be used as this dissolves in the hot glycerol and the precipitate formed is the desired product.
- vigorous stirring is needed to produce a small general particle size product with a preferable variation in crystal size and a talc-like, but non-greasy feel.
- the mixture should be kept at about 260°C for about 1 hour to ensure reaction has gone to completion.
- the increased viscosity is noted in the tem- perature range 195-220°C.
- the material can be heated for longer than one hour at the maximum temperature if residual zinc oxide is still present.
- the suspension, of the complex in the excess glycerol can be diluted with ethanol and this can be distilled off during the next process before further zinc oxide is added and the process repeated.
- the theoretical zinc content on dried product is 42.06%.
- OMPI was 86 gms or 90% (theoretical yield: 95.45gms).
- the I.R. was identical to literature values.
- Assay Zn content actual 43.56% (theoretical 42.06%).
- the glycerol was heated to 120°C with stirring.
- Zinc oxide 50g, 0.614 moles was added at this temperature to form a well dispersed suspension.
- the mixture was then slowly heated with vigorous stirring to 260 C. During the heating process, two changes in viscosity were noted. The first was a thickening of the reaction mixture to an almost paste consistency, then upon further heating the reaction mixture became less viscous.
- the crystals produced by this method consisted of a mixture of small hexagonal plates ( ⁇ lO microns) and elongated crystals.
- Example 2 As per Example 1 except zinc acetate (50gms, 0.23 moles . ) was used instead of zinc oxide.
- the product zinc glycerolate was isolated as above in 85% yield.
- the particle size varied from 10-70 microns, while the crystals were a mixture of elongated filament clusters and platlet structures.
- the high insolubility of zinc glycerolate in water and organic solvents means that crystals cannot be obtained by growth from solution.
- zinc glycerolate is related in part to its small but varying crystal size and crystal shape, the product produced by the reaction of zinc acetate and glycerol producing larger crystals than the reaction of zinc oxide with the latter.
- OMPI or prophylactic treatments other substances can be added as an admixture or as a means of producing further reaction products, and for example an aqueous solution of a copper salt may be added to the zinc glycerolate to replace small amounts of zinc in the complex by copper, resulting in a colour change and the ability to bring trace amounts of copper into contact with the skin when used as an ointment.
- aqueous solution of a copper salt may be added to the zinc glycerolate to replace small amounts of zinc in the complex by copper, resulting in a colour change and the ability to bring trace amounts of copper into contact with the skin when used as an ointment.
- EXAMPLE 5 A weak neutral solution of cupric chloride was shaken with a little zinc glycerolate, the mixture was filtered through a Buchner funnel and the residue washed in turn with alcohol and acetone. The product so formed was blue in colour.
- a further example may be given by the chemical absorption of suitable dyes by the zinc glycerolate giving a resultant obvious or non-obvious coloration when applied to the skin without destruction of the lubricity, or tactile qualities that make the original zinc compound advantageous for particular applications .
- Zinc glycerolate which was tan in colour was obtained by the addition of certolake erythrosine (O.lg) and certolake tartrazine (0.4g) to zinc oxide (40g) prior to reaction with glycerol in the manner described in Example 1.
- zinc glycerolate as a topical application is not limited to its combination with metal cations or dye-stuffs given in the examples
- OMPI IPO various skin disorders arising out of exposure to sunlight, while presenting properties of a non- apparent topical application.
- the zinc glycerolate complex has been found to be effective in the treatment and prevention of a ⁇ moniacal dermatitis (burns in the genital areas of babies which originate from ammonia liberated during the de ⁇ composition of urine - nappy rash) , in the treatment of pruritus, especially in people confined to bed or immobility, for the alleviation of psoriasis, for the treatment and prevention of fungal or bacteriacidal decomposition of tissue and the resultant odours arising in such complaints as tinea pedis and for the prevention of industrial dermatitus arising from particular environments. It is also envisaged that the properties of this compound would make it effective in the treatment of ichthyosis.
- This invention is not restricted to the use of zinc glycerolate in only the above therapeutic and prophylactic applications but it embraces all other use of this compound when reacted or blended with other therapeutic substances.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Materials Engineering (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE813152555T DE3152555T1 (de) | 1980-11-24 | 1981-11-18 | Pharmaceutical compound and method |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPE660280 | 1980-11-24 | ||
| AU6602/80 | 1980-11-24 | ||
| AUPF017681 | 1981-08-11 | ||
| AU176/81810811 | 1981-08-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1982001867A1 true WO1982001867A1 (en) | 1982-06-10 |
Family
ID=25642428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/AU1981/000164 WO1982001867A1 (en) | 1980-11-24 | 1981-11-18 | Pharmaceutical compound and method |
Country Status (5)
| Country | Link |
|---|---|
| JP (1) | JPH0256337B2 (enrdf_load_stackoverflow) |
| DE (1) | DE3152555T1 (enrdf_load_stackoverflow) |
| FR (1) | FR2494583B1 (enrdf_load_stackoverflow) |
| GB (1) | GB2101132B (enrdf_load_stackoverflow) |
| WO (1) | WO1982001867A1 (enrdf_load_stackoverflow) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3913194A1 (de) * | 1988-04-22 | 1989-11-02 | Medvet Science Pty Ltd | Entzuendunshemmende oder reizmildernde zinksalzzubereitung |
| GB2191941B (en) * | 1985-08-27 | 1990-03-14 | Glyzinc Pharma Ltd | Zinc glycerolate complex and additions for pharmaceutical applications |
| WO1994002131A1 (en) * | 1992-07-17 | 1994-02-03 | Glyzinc Pharmaceuticals Limited | Treatment of herpetic diseases |
| WO1994002132A1 (en) * | 1992-07-17 | 1994-02-03 | Glyzinc Pharmaceuticals Limited | Treatment of skin diseases |
| WO1994028884A1 (en) * | 1993-06-15 | 1994-12-22 | Glyzinc Pharmaceuticals Limited | Zinc monoglycerolate complex for anti-rejection treatment of the human or animal body |
| WO1995008524A1 (en) * | 1993-09-23 | 1995-03-30 | Pharmaserve Limited | Zinc glycerolate manufacture |
| US11969734B2 (en) | 2018-05-29 | 2024-04-30 | Deasyl Sa | Three-dimensional grinder, method for implementing same and uses thereof |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01502267A (ja) * | 1986-12-30 | 1989-08-10 | ホールズワース アンド アソシエイツ プロプライエタリー リミテッド | マイクロ波輻射の使用による金属アルコキシドおよび金属粉末の形成におけるまたはそれに係る改良 |
| JP6065520B2 (ja) * | 2012-10-24 | 2017-01-25 | 堺化学工業株式会社 | 酸化亜鉛粒子の製造方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3996346A (en) * | 1975-03-18 | 1976-12-07 | Dominic Thomas Staffier | Composition for reducing bodily odor and perspiration |
| US4160821A (en) * | 1978-02-27 | 1979-07-10 | Johnson & Johnson | Treatment for gingivitis |
-
1981
- 1981-11-18 JP JP56503590A patent/JPH0256337B2/ja not_active Expired - Lifetime
- 1981-11-18 GB GB08218746A patent/GB2101132B/en not_active Expired
- 1981-11-18 WO PCT/AU1981/000164 patent/WO1982001867A1/en active Application Filing
- 1981-11-18 DE DE813152555T patent/DE3152555T1/de active Granted
- 1981-11-23 FR FR8121914A patent/FR2494583B1/fr not_active Expired
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3996346A (en) * | 1975-03-18 | 1976-12-07 | Dominic Thomas Staffier | Composition for reducing bodily odor and perspiration |
| US4160821A (en) * | 1978-02-27 | 1979-07-10 | Johnson & Johnson | Treatment for gingivitis |
Non-Patent Citations (1)
| Title |
|---|
| TAYLOR et al: "AUSTRALIAN JOURNAL of CHEMISTRY, 1970, 23, 1963-71 (CSIRO, MELBOURNE) * |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2191941B (en) * | 1985-08-27 | 1990-03-14 | Glyzinc Pharma Ltd | Zinc glycerolate complex and additions for pharmaceutical applications |
| DE3913194A1 (de) * | 1988-04-22 | 1989-11-02 | Medvet Science Pty Ltd | Entzuendunshemmende oder reizmildernde zinksalzzubereitung |
| WO1994002131A1 (en) * | 1992-07-17 | 1994-02-03 | Glyzinc Pharmaceuticals Limited | Treatment of herpetic diseases |
| WO1994002132A1 (en) * | 1992-07-17 | 1994-02-03 | Glyzinc Pharmaceuticals Limited | Treatment of skin diseases |
| WO1994002133A1 (en) * | 1992-07-17 | 1994-02-03 | Glyzinc Pharmaceuticals Limited | Treatment of burns |
| WO1994028884A1 (en) * | 1993-06-15 | 1994-12-22 | Glyzinc Pharmaceuticals Limited | Zinc monoglycerolate complex for anti-rejection treatment of the human or animal body |
| WO1995008524A1 (en) * | 1993-09-23 | 1995-03-30 | Pharmaserve Limited | Zinc glycerolate manufacture |
| US11969734B2 (en) | 2018-05-29 | 2024-04-30 | Deasyl Sa | Three-dimensional grinder, method for implementing same and uses thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| DE3152555C2 (enrdf_load_stackoverflow) | 1991-01-03 |
| JPH0256337B2 (enrdf_load_stackoverflow) | 1990-11-29 |
| GB2101132B (en) | 1985-05-15 |
| FR2494583B1 (fr) | 1985-10-11 |
| JPS57501783A (enrdf_load_stackoverflow) | 1982-10-07 |
| GB2101132A (en) | 1983-01-12 |
| FR2494583A1 (fr) | 1982-05-28 |
| DE3152555T1 (de) | 1982-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU554151B2 (en) | Pharmaceutical compound and method | |
| DE69213159T2 (de) | Addukte von ton und aktivierten gemischten metalloxyden | |
| DE2327087C3 (enrdf_load_stackoverflow) | ||
| US4919922A (en) | Polyolefin-treated pigment and cosmetics containing the same | |
| DE2233748B2 (de) | Zahnreinigungsmittel | |
| DE2036819C3 (de) | Verfahren zur Herstellung von silikatischen Adsorptions- und Trocknungsmitteln | |
| WO1982001867A1 (en) | Pharmaceutical compound and method | |
| US5718908A (en) | Topical formulations based on mineral gels | |
| JPH02251240A (ja) | 紫外線吸収剤内包マイクロカプセル及びその製造方法並びにそのマイクロカプセルを含有する化粧料 | |
| DE60012151T2 (de) | Deodorantzusammensetzungen | |
| DE4134540A1 (de) | Desinfizierende keramikzusammensetzung | |
| US2761867A (en) | Aluminum salts of allantoin and their preparation and compositions comprising the same | |
| JP3838391B2 (ja) | 化粧料 | |
| JPS63250309A (ja) | 抗菌剤 | |
| CH638676A5 (de) | Karies verhinderndes mittel. | |
| JP2608786B2 (ja) | 粉末化粧料 | |
| US2177197A (en) | Composition of matter | |
| JPH0458443B2 (enrdf_load_stackoverflow) | ||
| JPH05194174A (ja) | 化粧用顔料およびその製造方法ならびに化粧料 | |
| US2407247A (en) | Bonded adsorbent | |
| DE2514878A1 (de) | Allantoin-ascorbinsaeure-komplex | |
| JPS61257910A (ja) | 化粧料 | |
| JP2865380B2 (ja) | 抗菌性化粧料 | |
| JPH0543682B2 (enrdf_load_stackoverflow) | ||
| JP3534120B2 (ja) | 合成雲母複合体を配合した化粧料 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Designated state(s): AU DE GB JP US |
|
| RET | De translation (de og part 6b) |
Ref document number: 3152555 Country of ref document: DE Date of ref document: 19821202 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 3152555 Country of ref document: DE |